|Targets||Sphingosine 1 Phosphate Receptor|
|Description||Ozanimod, also known as RPC1063, is a selective oral S1P Receptor 1 modulator.|
|B0084-470834||50 mg||$198||In stock|
|Synonyms||RPC1063; RPC-1063; RPC 1063; Ozanimod; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile|
|Solubility||DMSO: 81mg/mL(200.26mM); Ethanol: 10mg/mL(24.72mM); Water: <1mg/mL(<1mM)|
|Storage||3 years -20℃ powder; 6 months -80℃ in solvent|
|Shelf Life||2 years|
Ozanimod, also known as RPC1063, is a selective oral S1P Receptor 1 modulator.
The hydrochloride salt form of CYM 50358, which has been found to be an effective S1P4 antagonist.
The hydrochloride salt form of PF-543, a novel SphK1 inhibitor that could exhibit activity in induceing necrosis in human colorectal cancer cells in biological ...
CS-0777 is a selective sphingosine 1-phosphate receptor modulator agonist. It is in clinical trials for the treatment of multiple sclerosis, but no recent devel...
CYM 50308 has been found to be an effective and selective S1P4 agonist.
CYM 50260 has been found to be a S1P4 agonist.
This active molecular is a selective S1P1 receptor agonist that originated by Bristol-Myers Squibb. BMS-520 shows really good efficacy in animal models of arthr...
This active molecular is a S1P1/S1P5 agonist with limited activity at S1P3. AMG 369 has no activity at S1P2 and S1P4. AMG-369 is shown to reduce blood lymphocyt...